Investor Relations

Latest Financial Results

Q3 2022

Quarter Ended September 30, 2022

Latest Annual Filing

For Fiscal Year Ending December 31, 2021

Company Overview

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis and inflammation using anti-TNF, with its lead program in phase 2b/3 clinical trial.

Stock Snapshot

IR Contacts

Headquarters

180 Life Sciences Corp.
3000 El Camino Real
Bldg. 4, Suite 200
Palo Alto, CA 94306
info@180lifesciences.com

Investor Relations

Jason Assad
T: 678-570-6791
Jason@180lifesciences.com

Transfer Agent

Continental Stock Transfer & Trust Company
cstmail@continentalstock.com